 Panitumumab is a fully human anti-epidermal factor receptor 1 (HER1) monoclonal antibody (mAb) that has been approved by the United States Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancers that express the EGFR and are unresponsive to chemotherapy (1). This mAb has a very high affinity for the extracellular domain III of the HER1. The mode of action of panitumumab has been illustrated by Dubois and Cohen (1), and the general characteristics of this mAb have been described by Argiles et al. (2). The fully human mAb is well tolerated by individuals, slows disease progression, and improves the progression-free survival of patients (3). Therefore, 